• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Hypofractionated radiation therapy in keratinocyte carcinoma

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Tsao, M. N.
    Barnes, E. A.
    Karam, I.
    Rembielak, Agata
    Affiliation
    Department of Radiation Oncology, Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Hypofractionated radiation therapy regimens are well suited to the management of keratinocyte carcinomas. Most lesions are small, superficial and not close to critical organs at risk. Fewer visits to the cancer centre are advantageous for the frail and elderly patient population. No difference in cosmesis or local control has been found when comparing hypofractionated with conventionally fractionated radiation therapy schedules, although most of the data in the literature are retrospective, highlighting the need for prospective trials. As keratinocyte carcinomas can present anywhere on the skin surface, a wide variety of techniques may be used to optimise treatment delivery, including external beam radiation with kilovoltage, electron beams and megavoltage photons. Brachytherapy can also be used with radionuclide and electronic-based applicators, surface applicators and interstitial techniques for lesions >5 mm deep. Stereotactic body radiotherapy, or extreme hypofractionation, is an emerging treatment option that delivers an ablative dose to the tumour while minimising dose to organs at risk through precision planning and delivery techniques. Frail elderly patients with medically inoperable disease not suitable for conventionally fractionated radiation therapy may achieve durable locoregional control with dose escalation. Ongoing studies following local control and toxicity are warranted. The aim of this article is to provide clinical oncologists with an overview of hypofractionation for keratinocyte carcinomas.
    Citation
    Tsao MN, Barnes EA, Karam I, Rembielak A. Hypofractionated Radiation Therapy in Keratinocyte Carcinoma. Clinical Oncology. 2022 May;34(5):E218-E24. PubMed PMID: WOS:000821121800004.
    Journal
    Clinical Oncology
    URI
    http://hdl.handle.net/10541/625530
    DOI
    10.1016/j.clon.2022.02.016.
    PubMed ID
    35260318
    Additional Links
    https://dx.doi.org/10.1016/j.clon.2022.02.016.
    Type
    Article
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.clon.2022.02.016.
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
    • Authors: Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N, PACE Trial Investigators
    • Issue date: 2019 Nov
    • Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    • Authors: Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M, Rieken S
    • Issue date: 2020 Aug 26
    • Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis.
    • Authors: Zaorsky NG, Lee CT, Zhang E, Keith SW, Galloway TJ
    • Issue date: 2017 Oct
    • Hypofractionation for clinically localized prostate cancer.
    • Authors: Hickey BE, James ML, Daly T, Soh FY, Jeffery M
    • Issue date: 2019 Sep 3
    • Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    • Authors: Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P
    • Issue date: 2019 Aug 3
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.